Pharmacopsychiatry 2024; 57(02): 89
DOI: 10.1055/s-0044-1779566
Abstracts │ XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP
Lecture Abstracts

Pharmacogenetics in Psychiatry: Precision medicine or ‘mystic, magic, and mysterious’?

D. J. Müller
1   Department of Psychiatry, University of Toronto, Toronto, Canada
2   Centre for Addiction and Mental Health, Toronto, Canada
3   Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital of Würzburg, Würzburg, Germany
› Author Affiliations

Prescribers and patients are frequently facing the challenge that treatment standards established at a population level might not be beneficial at the individual level. As a result, lengthy trials are often required before the optimum psychiatric medication treatment, single or in combination, is found. The underlying reasons for this large inter-individual variability treatment outcomes are not fully understood. Important factors that influence drug dose, response and side effects include age, gender, patient compliance, clinical symptoms, co-morbidities, lifestyle, ancestry and genetic factors. In this context, first strategies using pharmacogenetic (PGx) information bear the promise to optimize medication treatment in clinical practice. State-of-the-art summaries of key concepts and strategies of psychiatric PGx need to consider: 1) Reviews of the evidence, clinical utility and studies including randomized clinical trials of distinct gene-drug pairs; 2) Discussion of current expert recommendations (e.g., Clinical Pharmacogenomics Implementation Consortium); 3) How PGx information can be best used in clinical practice, in particular to avoid pseudo-resistance for antidepressants 3) Highlighting ongoing implementation efforts and 5) providing practical support for psychiatrists and pharmacologists.

Publication History

Article published online:
12 March 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany